ABBV vs UNH: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and UnitedHealth Group Incorporated — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
UnitedHealth Group Incorporated · Healthcare
$353.52
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
UNH has more upside to fair value
(+45.0%).
UNH trades at a lower forward P/E
(26.7x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
UNH |
| Current Price |
$197.69 |
$353.52 |
| Fair Value Estimate |
$210.22 |
$512.60 |
| Upside to Fair Value |
+6.3%
|
+45.0%
|
| Market Cap |
$349.7B |
$320.9B |
| Forward P/E |
83.3x
|
26.7x
|
| EV / EBITDA |
23.4x
|
16.1x
|
| Price / Sales |
5.7x
|
0.7x
|
| Price / FCF |
18.7x
|
16.3x
|
| Revenue Growth YoY |
+10.0%
|
+2.0%
|
| Gross Margin |
70.2%
|
18.8%
|
| Operating Margin |
26.7%
|
4.2%
|
| Return on Equity |
-361.6%
|
12.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
6.13%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
UnitedHealth Group Incorporated operates as a leading healthcare company with two main platforms: UnitedHealthcare, providing health benefits coverage, and Optum, offering information and technology services. The company benefits from a durable competitive moat due to its scale, integrated platforms, and broad market reach serving over 170 million consumers. Despite strong revenue growth of 12% y…
Accumulation Zones
| Metric |
ABBV |
UNH |
| Zone Low |
$157.66 |
$384.45 |
| Zone High |
$178.69 |
$435.71 |
| In Buy Zone? |
No
|
Yes
|